title: The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer.
abstract: Cytokine-induced killer (CIK) cells are ex vivo generated heterogeneous NK-like T lymphocytes. It is not very clear whether the phenotype of CIK cells is associated with their therapeutic efficacy to cancer patients. Thus, in this study, the association of phenotype of CIK cells and the overall survival of 121 patients with hepatocellular carcinoma (HCC), 74 patients with lung cancer and 42 patients with colorectal cancer, all of whom underwent surgical resection and received autogenous CIK cell therapy, was analyzed. We found that high ratio of the CD3+CD4+ subset was associated with poorer overall survival in colorectal cancer, but not HCC or lung cancer. A high ratio of the CD3+CD8+ subset was associated with improved overall survival in all three types of cancer. A high ratio of the CD3+CD56+ NK-like subset was associated with improved overall survival in lung and colorectal cancer, but not HCC. A high ratio of the CD3-CD56+ NK subset was associated with poorer overall survival in lung and colorectal cancer, but not HCC. In conclusion, the CD3+CD8+ and CD3+CD56+ subsets, especially the CD3+CD8+ subset, may be the major phenotypes responsible for anti-tumor immunity in vivo after autogenous CIK cell therapy.
authors: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
authors: Ke
authors: K
authors: Pan
authors: Qi-Jing
authors: QJ
authors: Wang
authors: Qing
authors: Q
authors: Liu
authors: Hai-Xia
authors: HX
authors: Zheng
authors: Yong-Qiang
authors: YQ
authors: Li
authors: De-Sheng
authors: DS
authors: Weng
authors: Jian-Jun
authors: JJ
authors: Li
authors: Li-Xi
authors: LX
authors: Huang
authors: Jia
authors: J
authors: He
authors: Shi-Ping
authors: SP
authors: Chen
authors: Miao-La
authors: ML
authors: Ke
authors: Yi-Xin
authors: YX
authors: Zeng
authors: Jian-Chuan
authors: JC
authors: Xia
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D055612:Cytokine-Induced Killer Cells / Q000276:immunology* / Q000378:metabolism*; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive; D008297:Male; D009369:Neoplasms / Q000276:immunology* / Q000401:mortality* / Q000628:therapy; D010641:Phenotype
chemical_list: D015703:Antigens, CD
references: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
references: 15980149
references: J Biomed Biotechnol. 2010;2010:435745
references: 20368995
references: J Immunother. 2012 Feb-Mar;35(2):189-95
references: 22306907
references: Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87
references: 21664472
references: J Transl Med. 2013 Mar 28;11:83
references: 23536996
references: Nat Med. 2009 Jul;15(7):808-13
references: 19525962
references: Blood. 2011 Jan 20;117(3):808-14
references: 20971955
references: J Exp Med. 1991 Jul 1;174(1):139-49
references: 1711560
references: Exp Hematol. 1993 Dec;21(13):1673-9
references: 7694868
references: Cell Immunol. 1996 Apr 10;169(1):85-90
references: 8612299
references: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74
references: 19805141
references: Immunology. 2009 Mar;126(3):423-35
references: 18778291
references: Expert Opin Biol Ther. 2012 Jun;12(6):673-84
references: 22500889
references: Br J Haematol. 1994 Jul;87(3):453-8
references: 7527643
references: J Immunol. 1994 Aug 15;153(4):1687-96
references: 7519209
references: J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10
references: 20407789
references: Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7
references: 15744236
references: Expert Opin Biol Ther. 2012 May;12(5):565-72
references: 22444075